Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors

Abstract

Autophagy inhibition has been shown to sensitize tumor cells to cell death induced by tyrosine kinase inhibitors (TKIs). The remarkable responses obtained in seven patients with the combination of clarithromycin and TKIs support the hypothesis that the inhibition of autophagy may make chronic myeloid leukemia cells sensitive to killing by TKIs.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Vignir Helgason G, Karvela M, Holyoake TL . Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011; 118: 2035–2043.

    Article  Google Scholar 

  2. 2

    Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119: 1109–1123.

    CAS  Article  Google Scholar 

  3. 3

    Calabretta B, Salamoni P . Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors. Leuk Lymphoma 2011; 52 (Suppl 1): 54–59.

    CAS  Article  Google Scholar 

  4. 4

    Jung CH, Ro SH, Cao J, Otto NM, Kim DH . mTOR regulation of autophagy. FEBS Lett 2010; 584: 1287–1295.

    CAS  Article  Google Scholar 

  5. 5

    Nakamura M, Kikukawa Y, Takeya M, Mitsuva H, Hata H . Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 2010; 37: 815–820.

    CAS  Google Scholar 

  6. 6

    Morris TC, Kettle PJ, Drake M et al. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Br J Haematol 2008; 143: 349–354.

    CAS  Article  Google Scholar 

  7. 7

    Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A et al. Clarithromycin (Biaxin)-lenalinomide-low-dose dexamethasone (BiRd) versus lenalinomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010; 85: 664–669.

    CAS  Article  Google Scholar 

  8. 8

    Carella AM, Lerma E, Corsetti MT, Dejana A, Basta P, Vassallo F et al. Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999; 93: 1534–1539.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to A M Carella.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

This article was published as part of a supplement that was supported by Novartis, MSD Italia, Roche, Celgene, GlaxoSmithKline, Sanofi, Gilead, Adienne, Italfarmaco, Pierre Fabre Pharmaceuticals with an unrestricted educational contribution to AREO—Associazione Ricerche Emato-Oncologiche (Genoa) and AMS—Associazione Malattie del Sangue (Milan) for the purpose of advancing research in acute and chronic leukemia.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carella, A., Beltrami, G., Catania, G. et al. Inhibition of autophagy with clarithromycin: a new strategy to enhance sensitivity of CML stem cells to tyrosine kinase inhibitors. Leukemia Suppl 1, S49–S50 (2012). https://doi.org/10.1038/leusup.2012.25

Download citation

Keywords

  • chronic myeloid leukemia
  • tyrosine kinase inhibitors
  • clarithromycin
  • autophagy

Search

Quick links